Indivior PLC (NASDAQ:INDV) Shares Bought by Centiva Capital LP

Centiva Capital LP boosted its position in shares of Indivior PLC (NASDAQ:INDV - Free Report) by 240.4% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 85,090 shares of the company's stock after acquiring an additional 60,090 shares during the quarter. Centiva Capital LP owned 0.06% of Indivior worth $830,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the company. Bank of New York Mellon Corp purchased a new stake in Indivior during the 2nd quarter worth about $188,000. VELA Investment Management LLC acquired a new position in shares of Indivior during the second quarter worth about $235,000. XTX Topco Ltd purchased a new stake in shares of Indivior during the second quarter worth approximately $249,000. Verition Fund Management LLC acquired a new stake in Indivior in the third quarter valued at approximately $375,000. Finally, Cubist Systematic Strategies LLC lifted its stake in Indivior by 32.0% in the second quarter. Cubist Systematic Strategies LLC now owns 25,236 shares of the company's stock worth $407,000 after acquiring an additional 6,121 shares during the last quarter. 60.33% of the stock is owned by institutional investors and hedge funds.

Indivior Stock Up 0.9 %

INDV traded up $0.10 on Friday, reaching $11.35. The company's stock had a trading volume of 1,606,084 shares, compared to its average volume of 1,232,905. The company has a market capitalization of $1.56 billion, a price-to-earnings ratio of -283.68 and a beta of 0.75. The company has a quick ratio of 0.65, a current ratio of 0.83 and a debt-to-equity ratio of 23.50. Indivior PLC has a fifty-two week low of $7.33 and a fifty-two week high of $23.22. The stock has a 50 day moving average of $9.79 and a two-hundred day moving average of $12.11.

Indivior (NASDAQ:INDV - Get Free Report) last posted its earnings results on Thursday, October 24th. The company reported $0.54 earnings per share for the quarter, beating the consensus estimate of $0.39 by $0.15. The business had revenue of $307.00 million during the quarter, compared to the consensus estimate of $302.25 million. Indivior had a negative return on equity of 351.08% and a negative net margin of 0.17%. As a group, analysts forecast that Indivior PLC will post 1.66 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have commented on INDV. Piper Sandler reissued an "overweight" rating and issued a $16.00 price objective (up from $15.00) on shares of Indivior in a research report on Friday, October 25th. Craig Hallum dropped their target price on Indivior from $20.00 to $16.00 and set a "buy" rating on the stock in a report on Friday, October 11th.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.